What does DIALEX BIOMEDICA SALES do?

DIALEX BIOMEDICA SALES is a wholesaler in Bilzen-Hoeselt. Private Limited, started on 25 August 1999, 1 establishment.

What is the address of DIALEX BIOMEDICA SALES?

The registered office of DIALEX BIOMEDICA SALES is located at Caetsbeekstraat 1, 3740 Bilzen-Hoeselt.

Is DIALEX BIOMEDICA SALES still active?

Yes. According to the CBE (31 October 2026) DIALEX BIOMEDICA SALES is active, legal situation “Normale toestand”, started on 25 August 1999.

Is DIALEX BIOMEDICA SALES registered on Peppol?

Yes, DIALEX BIOMEDICA SALES is registered on the Peppol network with ID 0208:0466736977.

What is the enterprise number of DIALEX BIOMEDICA SALES?

The enterprise number of DIALEX BIOMEDICA SALES is BE0466736977.

When was DIALEX BIOMEDICA SALES founded?

DIALEX BIOMEDICA SALES was founded on 25 August 1999.

Who are the directors of DIALEX BIOMEDICA SALES?

According to the 2025 annual accounts, the directors of DIALEX BIOMEDICA SALES are: Michaël Barthels.

Is DIALEX BIOMEDICA SALES a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 25 August 1999; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DIALEX BIOMEDICA SALES make in 2025?

DIALEX BIOMEDICA SALES posted a profit after taxes of € 6,281,374 in financial year 2025.

What is the revenue of DIALEX BIOMEDICA SALES?

As a small company, DIALEX BIOMEDICA SALES is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 222,791.

How much does an employee at DIALEX BIOMEDICA SALES earn?

The average wage cost per full-time employee at DIALEX BIOMEDICA SALES was € 56,500 in 2025: staff costs of € 67,790 for 1.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does DIALEX BIOMEDICA SALES have?

According to the 2025 annual accounts, DIALEX BIOMEDICA SALES has 1.2 full-time equivalents (FTE).

DIALEX BIOMEDICA SALES (Private Limited) - Bilzen-Hoeselt

Dossier DIALEX BIOMEDICA SALES, printed on 1 November 2026 from databakkes.be/en/0466736977/dialex-biomedica-sales. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DIALEX BIOMEDICA SALES from Bilzen-Hoeselt, company number BE0466736977, closed financial year 2025 with a result of € 6.3 million after tax. For that financial year DIALEX BIOMEDICA SALES recorded a gross margin of € 222,791 and equity of € 19.6 million. Compared with financial year 2024, the result moved from € 2.7 million to € 6.3 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 23, 2025.

What it is worth Growing

€ 19.6 million

▲ 36% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 6.3 million

▲ 132% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 2.5 million

▲ 99% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1 million paid out

16 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

1.2

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 67,790

▼ 22% vs 2024

€ 56,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 25,083

▼ 40% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 14,048

▼ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 560,628

▲ € 519,723 vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 513,020 Revenue 2022: € 513,020 First fiscal year in the series	€ 511,240 Revenue 2023: € 511,240 Unchanged (€ 513,020) Unfavourable step	€ 512,887 Revenue 2024: € 512,887 Unchanged (€ 511,240) Favourable step	-
Gross margin	-	-	-	€ 222,791 Gross margin 2025: € 222,791 First fiscal year in the series
Profit after taxes	€ 1,776,661 Profit after taxes 2022: € 1,776,661 First fiscal year in the series	€ 2,462,059 Profit after taxes 2023: € 2,462,059 ▲ 39% vs 2022 (€ 1,776,661) Favourable step	€ 2,709,114 Profit after taxes 2024: € 2,709,114 ▲ 10% vs 2023 (€ 2,462,059) Favourable step	€ 6,281,374 Profit after taxes 2025: € 6,281,374 ▲ 132% vs 2024 (€ 2,709,114) Favourable step	▲ 132%
Equity	€ 9,850,711 Equity 2022: € 9,850,711 First fiscal year in the series	€ 11,847,113 Equity 2023: € 11,847,113 ▲ 20% vs 2022 (€ 9,850,711) Favourable step	€ 14,385,092 Equity 2024: € 14,385,092 ▲ 21% vs 2023 (€ 11,847,113) Favourable step	€ 19,633,155 Equity 2025: € 19,633,155 ▲ 36% vs 2024 (€ 14,385,092) Favourable step	▲ 36%
Total debts	€ 744,181 Total debts 2022: € 744,181 First fiscal year in the series	€ 720,506 Total debts 2023: € 720,506 ▼ 3% vs 2022 (€ 744,181) Favourable step	€ 635,472 Total debts 2024: € 635,472 ▼ 12% vs 2023 (€ 720,506) Favourable step	€ 1,117,963 Total debts 2025: € 1,117,963 ▲ 76% vs 2024 (€ 635,472) Unfavourable step	▲ 76%
Cash	€ 715,450 Cash 2022: € 715,450 First fiscal year in the series	€ 312,552 Cash 2023: € 312,552 ▼ 56% vs 2022 (€ 715,450) Unfavourable step	€ 1,238,496 Cash 2024: € 1,238,496 ▲ 296% vs 2023 (€ 312,552) Favourable step	€ 2,459,250 Cash 2025: € 2,459,250 ▲ 99% vs 2024 (€ 1,238,496) Favourable step	▲ 99%
Land & buildings	€ 2,535,213 Land & buildings 2022: € 2,535,213 First fiscal year in the series	€ 2,436,131 Land & buildings 2023: € 2,436,131 ▼ 4% vs 2022 (€ 2,535,213) Unchanged	€ 2,322,998 Land & buildings 2024: € 2,322,998 ▼ 5% vs 2023 (€ 2,436,131) Unchanged	€ 2,202,943 Land & buildings 2025: € 2,202,943 ▼ 5% vs 2024 (€ 2,322,998) Unchanged	▼ 5%
Retained profit	€ 9,830,711 Retained profit 2022: € 9,830,711 First fiscal year in the series	€ 11,827,113 Retained profit 2023: € 11,827,113 ▲ 20% vs 2022 (€ 9,830,711) Favourable step	€ 14,365,092 Retained profit 2024: € 14,365,092 ▲ 21% vs 2023 (€ 11,827,113) Favourable step	€ 19,613,155 Retained profit 2025: € 19,613,155 ▲ 37% vs 2024 (€ 14,365,092) Favourable step	▲ 37%
Dividend	€ 984,143 Dividend 2022: € 984,143 First fiscal year in the series	€ 465,658 Dividend 2023: € 465,658 ▼ 53% vs 2022 (€ 984,143) Unchanged	€ 171,135 Dividend 2024: € 171,135 ▼ 63% vs 2023 (€ 465,658) Unchanged	€ 1,033,311 Dividend 2025: € 1,033,311 ▲ € 862,177 vs 2024 (€ 171,135) Unchanged	▲ € 862,177
Bank debt	€ 676,988 Bank debt 2022: € 676,988 First fiscal year in the series	€ 621,507 Bank debt 2023: € 621,507 ▼ 8% vs 2022 (€ 676,988) Favourable step	€ 565,153 Bank debt 2024: € 565,153 ▼ 9% vs 2023 (€ 621,507) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 565,153) Favourable step	▼ 100%
Balance sheet total	€ 10,594,893 Balance sheet total 2022: € 10,594,893 First fiscal year in the series	€ 12,567,619 Balance sheet total 2023: € 12,567,619 ▲ 19% vs 2022 (€ 10,594,893) Unchanged	€ 15,020,564 Balance sheet total 2024: € 15,020,564 ▲ 20% vs 2023 (€ 12,567,619) Unchanged	€ 20,751,119 Balance sheet total 2025: € 20,751,119 ▲ 38% vs 2024 (€ 15,020,564) Unchanged	▲ 38%
Employees (FTE)	0.1 Employees (FTE) 2022: 0.1 First fiscal year in the series	1.2 Employees (FTE) 2023: 1.2 ▲ 1.1 vs 2022 (0.1) Unchanged	1.2 Employees (FTE) 2024: 1.2 Unchanged (1.2) Unchanged	1.2 Employees (FTE) 2025: 1.2 Unchanged (1.2) Unchanged

Key figures of DIALEX BIOMEDICA SALES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to DIALEX BIOMEDICA SALES?

What happened at DIALEX BIOMEDICA SALES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 23, 2025 New annual accounts for financial year 2025: profit of € 6.3 million (▲ 132% vs 2024). Source: NBB ↗
2005 Michaël Barthels became a director. NBB
Oct 7, 1999 New establishment in Hasselt. KBO
Aug 25, 1999 Start of the company according to the CBE. KBO

In short

From € 1.8 million profit in 2022 to € 6.3 million profit in 2025.

Paid € 928,920 in corporate taxes since 2022.

Best year ever: 2025, with € 6.3 million profit.

On average € 185,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Michaël Barthels

DIALEX BIOMEDICA SALES

Dialex Biomedica 99.8%

Behind DIALEX BIOMEDICA SALES is Michaël Barthels. It owns 99.8% of Dialex Biomedica itself.

Directors

According to the 2025 annual accounts

Michaël Barthels

Director

since 2005

Establishments

Establishment units

Physical locations of this company

Registered office

Caetsbeekstraat 1

3740 Bilzen-Hoeselt

2.092.446.584

Luikersteenweg 140A box 2

3500 Hasselt

Active since 7 October 1999

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

DIALEX BIOMEDICA same network

€ 4 million gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0466.736.977

VAT number

BE 0466.736.977

Registered office

Caetsbeekstraat 1, 3740 Bilzen-Hoeselt

Names & denominations

DIALEX BIOMEDICA SALES

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

25 August 1999

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Handelsbemiddeling in de groothandel in andere specifieke goederen

Activiteiten van holdings

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

Ontwikkeling van residentiële bouwprojecten

Verhuur en exploitatie van terreinen

View on CBE Public ↗ Annual accounts (NBB) ↗

DIALEX BIOMEDICA SALES

Financials

What happened to DIALEX BIOMEDICA SALES?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions